Coverage from the ASCO20 Virtual Scientific Program
Focus on Metastatic Colorectal Cancer
Article Update: Biomarkers Identified to Guide Treatment Duration in Stage III Colorectal Cancer
Researchers have identified histologic biomarkers that could guide treatment decisions for adjuvant therapy in stage III colorectal cancer (CRC). Results were presented at the ASCO 2020 virtual sessions (J Clin Oncol 2020;38:(suppl; abstr 4065),and published in April 2020 in the Annals of Oncology (2020 31:487-494).
Positive Results for Off-the-Shelf Metastatic CRC Immunotherapy
Researchers presented positive final data from a phase I/II study of PolyPEPI1018, an off-the-shelf multi-peptide treatment, in microsatellite stable metastatic colorectal cancer (MSS mCRC) patients during an online poster presentation at the 2020 ASCO Annual Meeting (Abstract 4048).
Pembrolizumab Effective, Produces Durable Responses Over 3 Years in MSI-H mCRC
Long-term treatment with pembrolizumab was associated with durable responses and significant antitumor immunity over 3 years in patients with advanced colorectal cancer (CRC) and metastatic microsatellite instability-high (MSI-H) tumors who were enrolled in the phase II KEYNOTE-164 study. This is according study author Luis A. Diaz, MD, of the Memorial Sloan Kettering Cancer Center, who presented the findings from the trial at the ASCO 2020 Annual Meeting (Abstract 4032).
New! Survival Outcomes for Older Colorectal Cancer Patients With Second-Line Therapy
Fewer older adults with metastatic colorectal cancer participate in second-line randomized clinical trials, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 7009). The researchers also reported that that the survival outcomes among older adults enrolled in second-line trials was similar to younger patients.
The Survival Benefit of FOLFOXIRI + Bevacizumab in Metastatic Colorectal Cancer
Data demonstrated that metastatic colorectal cancer patients who received FOLFOXIRI plus bevacizumab had a statistically significant improvement in overall survival (OS) compared to those who were treated with doublet therapy and bevacizumab. The researchers also reported a meaningful effect on 5-year OS, progression-free survival (PFS), objective response rate (ORR), and R0 resection rate, according to the findings presented at the 2020 ASCO Annual Meeting (Abstract 4015).
Nivolumab + Ipilimumab Produces Durable Responses in Metastatic Colorectal Cancer
First-line nivolumab plus low-dose ipilimumab over a 2-year period was associated with durable clinical benefit and deepening responses and featured a good tolerability profile in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC), according to long-term follow-up data from the phase II CheckMate-142 trial, which were presented at the ASCO 2020 Annual Meeting (Abstract 4040).